PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29534964-0	2018	Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming.	Doxorubicin	53-64	phosphogluconate dehydrogenase	Homo sapiens	11-43	
29534964-0	2018	Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming.	NADP	120-125	phosphogluconate dehydrogenase	Homo sapiens	11-43	
29534964-3	2018	In our work, we identified that 6-phosphogluconate dehydrogenase (6PGD) is critically involved in the development of ATC resistance to doxorubicin.	Doxorubicin	135-146	phosphogluconate dehydrogenase	Homo sapiens	32-64	
29534964-3	2018	In our work, we identified that 6-phosphogluconate dehydrogenase (6PGD) is critically involved in the development of ATC resistance to doxorubicin.	Doxorubicin	135-146	phosphogluconate dehydrogenase	Homo sapiens	66-70	
29534964-4	2018	We found that 6PGD mRNA, protein and enzyme activity levels are significantly upregulated in ATC cells during the prolonged exposure to doxorubicin in a time-dependent manner.	Doxorubicin	136-147	phosphogluconate dehydrogenase	Homo sapiens	14-18	
29534964-5	2018	6PGD inhibition by genetic and pharmacological approaches significantly inhibits growth and survival of ATC cells that are highly resistant to doxorubicin.	Doxorubicin	143-154	phosphogluconate dehydrogenase	Homo sapiens	0-4	
29534964-6	2018	Consistently, 6PGD inhibition also sensitizes ATC cells to doxorubicin treatment.	Doxorubicin	59-70	phosphogluconate dehydrogenase	Homo sapiens	14-18	
29534964-7	2018	Of note, we observed the decreased level of NADPH, NADH and enzymatic activity of sirtuin-1 in response to 6PGD inhibition in doxorubicin-resistant ATC cells.	NADP	44-49	sirtuin 1	Homo sapiens	82-91	
29534964-7	2018	Of note, we observed the decreased level of NADPH, NADH and enzymatic activity of sirtuin-1 in response to 6PGD inhibition in doxorubicin-resistant ATC cells.	NADP	44-49	phosphogluconate dehydrogenase	Homo sapiens	107-111	
29534964-7	2018	Of note, we observed the decreased level of NADPH, NADH and enzymatic activity of sirtuin-1 in response to 6PGD inhibition in doxorubicin-resistant ATC cells.	NAD	51-55	phosphogluconate dehydrogenase	Homo sapiens	107-111	
29534964-7	2018	Of note, we observed the decreased level of NADPH, NADH and enzymatic activity of sirtuin-1 in response to 6PGD inhibition in doxorubicin-resistant ATC cells.	Doxorubicin	126-137	sirtuin 1	Homo sapiens	82-91	
29534964-7	2018	Of note, we observed the decreased level of NADPH, NADH and enzymatic activity of sirtuin-1 in response to 6PGD inhibition in doxorubicin-resistant ATC cells.	Doxorubicin	126-137	phosphogluconate dehydrogenase	Homo sapiens	107-111	
29534964-8	2018	Lactate level was also reduced by 6PGD inhibition.	Lactic Acid	0-7	phosphogluconate dehydrogenase	Homo sapiens	34-38	
29534964-9	2018	All these indicate that 6PGD inhibition disrupts metabolic reprogramming in doxorubicin-resistant ATC cells.	Doxorubicin	76-87	phosphogluconate dehydrogenase	Homo sapiens	24-28	
29534964-10	2018	Our work demonstrates 6PGD activation-mediated resistance in response to doxorubicin and provides an alternative therapeutic strategy to overcome resistance to chemotherapy for ATC treatment.	Doxorubicin	73-84	phosphogluconate dehydrogenase	Homo sapiens	22-26